ArticleFrontiers in pharmacology2025
Mechanistic insights into Jianpi Qinghua Sanyu Yin treatment of raised erosive gastritis: ceRNA-mediated PI3K/AKT signaling pathways.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Raised erosive gastritis (REG) is a chronic gastritis with a high risk of malignant transformation. Current treatments often result in high recurrence rates and complications. Jianpi Qinghua Sanyu Yin (JPQHSYY), a traditional Chinese medicine, shows promise in treating REG. However, the underlying molecular mechanisms remain unclear. This study aimed to investigate the potential mechanism of JPQHSYY's therapeutic effects on REG. Methods: RNA-seq was employed to systematically analyze mRNA, lncRNA, and miRNA profiles in gastric mucosal tissues from REG patients before and after JPQHSYY treatment. The pivotal lncRNA-miRNA and miRNA-mRNA networks were predicted from sequencing data and bioinformatic analysis, and the results were exported using Cytoscape software. Gene Ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were used for functional exploration. Real-time quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was performed to validate RNA-seq analysis results. CCK8, cell cycle, apoptosis and western blot were performed to detect the effects of miR-122-5p in GES-1 cells Results: RNA-seq analysis revealed 576 differentially expressed lncRNAs (269 upregulated, 307 downregulated), 33 differentially expressed miRNAs (13 upregulated, 20 downregulated), and 1717 differentially expressed mRNAs (777 upregulated, 940 downregulated) in JPQHSYY-treated REG patients. GO and KEGG analyses highlighted key pathways, including the PI3K/AKT signaling pathway, involved in cell cycle and apoptosis regulation. The ceRNA network analysis suggested that JPQHSYY impacts the miRNA-lncRNA interactions. Validation experiments confirmed that JPQHSYY inhibits the PI3K/AKT pathway, reducing cell viability, colony formation, and promoting apoptosis in miR-122-5p transfected GES-1 cells. Conclusion: The therapeutic efficacy of JPQHSYY in treating REG might be mediated by the ceRNA-driven PI3K/AKT pathway signaling pathways, which is implicated in the proliferation of gastric mucosal epithelial cells. Furthermore, the investigation of miRNA-lncRNA networks could reveal more information on potential new mechanisms and targets for JPQHSYY in the management of REG.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.